US 12,257,266 B2
Stem cell-derived exosomes for the treatment of corneal scarring
Sophie Xiaohui Deng, Los Angeles, CA (US); and James L. Funderburgh, Pittsburgh, PA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Appl. No. 16/977,015
Filed by The Regents of the University of California, Oakland, CA (US); and University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, CA (US)
PCT Filed Mar. 4, 2019, PCT No. PCT/US2019/020516
§ 371(c)(1), (2) Date Aug. 31, 2020,
PCT Pub. No. WO2019/169380, PCT Pub. Date Sep. 6, 2019.
Claims priority of provisional application 62/638,045, filed on Mar. 2, 2018.
Prior Publication US 2021/0000858 A1, Jan. 7, 2021
Int. Cl. A61K 31/7105 (2006.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/7105 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); C12N 15/113 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01)] 7 Claims
 
1. A pharmaceutical composition comprising:
a plurality of polynucleotides comprising SEQ ID NO: 1-SEQ ID NO: 107; and
a pharmaceutical excipient selected from the group consisting of:
a preservative, a tonicity adjusting agent, a detergent, a viscosity adjusting agent, a sugar or a pH adjusting agent.